



Press Release
Amlodipine Besylate Tablets

Contact:

Suzanne Collier
Marketing Communications
(888) TEVA USA

Teva Introduces Amlodipine Besylate Tablets

North Wales, Pennsylvania, July 10, 2007 – Teva Pharmaceuticals is pleased to announce the introduction and availability of Amlodipine Besylate Tablets. This product is AB rated and bioequivalent to Norvasc®* Tablets. Amlodipine Besylate Tablets are available in 2.5 mg, 5 mg and 10 mg strengths in bottle sizes of 90 tablets and 5 mg strength in bottle sizes of 300 tablets.

“Our customers count on Teva for a continuous supply of new generic products,” states John Denman, Vice President, Sales and Marketing. “With the launch of Amlodipine Besylate Tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”

Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡

* Norvasc® is a registered trademark of Pfizer Inc.

‡ Data on file, Teva USA.

Please see accompanying prescribing information.

Administrative Offices:

1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090
Phone: 215.591.3000 Fax: 215.591.8600 www.tevausea.com